What changed
$KEYS — AVOID 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ2 FY2026 (ends Apr) | reported May 19 | Rev $1.7B | EPS $2.87 vs $2.32 🟢 | Margin 33.3%
💡 Consensus expected $2.32 EPS, but actual $2.87 beat estimates. However, the beat was fueled by margin improvements (operating margin 33.3%) likely near peak, not revenue growth. The market may be over-extrapolating one-time efficiency gains into future periods, setting up disappointment if margins mean-revert.
🏢 Business Quality: 7/10
📊 Valuation: rich — trailing P/E 28.6x, PEG misleadingly low at 0.42 given unsustainable 68% y/y EPS growth, price/sales 32.7x.
🔮 Catalyst: Next quarterly earnings release (estimated Oct 2026)
⚖️ Avoid KEYS at $328.66; 28.6x trailing earnings and flat revenue offer poor reward/risk for a long, despite strong EPS beat.